Syneos Health

Syneos Health, Inc. engages in the provision of outsourced clinical development and commercialization services to biopharmaceutical companies. It operates through the following business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers clinical development services spanning Phase I to Phase IV, including global studies, as well as unbundled service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. The company was founded in 1998 and is headquartered in Morrisville, NC.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Syneos Health reports mixed Q4 results, focuses on growth strategies

Syneos Health's Q4 performance showed mixed results with revenue decline but growth on a constant currency basis. The company is focused on enhancing its operating model, customer engagement, and winning new business opportunities.
Challenges include evaluating spending by large pharma customers and the need for cost structure realignment. However, opportunities lie in engaging with analysts, driving cost savings, and expecting larger pharma awards in 2023.
Overall, Syneos Health remains confident in its strategy, investments, and ability to drive growth in Clinical. The company is navigating challenges while leveraging strengths in customer relationships and value-based pricing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Syneos Health, Inc. (“Syneos” or the “Company”) (NASDAQ: SYNH) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Syneos securities between September 9, 2020 and November 3, 2022, both dates inclusive (the “Class Period”). Inves.

SYNEOS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Syneos Health, Inc. and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Syneos Health, Inc. (“Syneos” or the “Company”) (NASDAQ: SYNH) common stock between September 9, 2020 and November 3, 2022, inclusive (the “Class Period”). Syneos investors have until September 25, 2023 to file a lead plaintiff motion. If you suffered a loss on your S.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Syneos Health, Inc. (SYNH) Investors

NEW YORK , Aug. 3, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Syneos Health, Inc. (NASDAQ: SYNH) between September 9, 2020 and November 3, 2022, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Syneos Health, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SYNH

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Syneos Health, Inc. (“Syneos” or the “Company”) (NASDAQ: SYNH) common stock between September 9, 2020 and November 3, 2022, inclusive (the “Class Period”). Syneos investors have until September 25, 2023 to file a lead plaintiff motion. Investors suffering losses on their Syneos investments are encouraged to contact the Law Offices of Howard G.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Syneos Health, Inc. (SYNH) Investors

MORRISVILLE, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today announced that the Company's stockholders approved an agreement to take the Company private through an acquisition by a consortium of private investment firm affiliates comprised of Elliott Investment Management L.P., Patient Square Capital, and Veritas Capital at a special meeting of stockholders held earlier today. As previously announced, under the terms of the agreement, Syneos Health stockholders will receive $43.00 in cash for each share of Syneos Health common stock owned at the closing of the transaction, if completed.

Syneos Health Stockholders Approve Agreement with Private Investment Consortium

NEW YORK--(BUSINESS WIRE)--Click Therapeutics announced the launch of an additional randomized clinical study in migraine, conducted in partnership with Syneos Health.

Click Therapeutics Launches Additional Randomized Clinical Study in Migraine, Conducted in Partnership with Syneos Health

LOS ANGELES, CA / ACCESSWIRE / August 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Syneos Health, Inc. ("Syneos" or "the Company") (NASDAQ:SYNH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 9, 2020 and November 3, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before September 25, 2023.

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Syneos Health, Inc. with Losses of $100,000 to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)---- $SYNH #Covid19--Syneos Health, Inc. (SYNH) Misled Investors Regarding its Business Prospects.

Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Syneos Health, Inc. (SYNH)

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Syneos Health, Inc. (“Syneos” or the “Company”) (NASDAQ: SYNH) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Syneos investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities law.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Syneos Health, Inc. (SYNH) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Syneos Health, Inc. (“Syneos” or the “Company”) (NASDAQ: SYNH) investors concerning the Company's possible violations of federal securities laws. On February 17, 2022, Syneos disclosed that its reimbursable expenses would likely never recover to pre-pandemic levels and that $3.8 billion of the Company's Clinical Solutions backlog was at risk of never being collected. On this news, Syneos's sto.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Syneos Health, Inc. (SYNH) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Syneos Health, Inc. (NASDAQ: SYNH) between September 9, 2020 and November 3, 2022, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 25, 2023. SO WHAT: If you purchased Syneos securities during the Cl.

SYNH EQUITY ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Syneos Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SYNH

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Syneos Health, Inc. (“Syneos” or the “Company”) (NASDAQ: SYNH) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 17, 2022, Syneos disclosed that its reimbursable expenses would likely never recover to pre-pandemic levels and that $3.8 billion of the Company's Clinical Soluti.

The Law Offices of Frank R. Cruz Announces Investigation of Syneos Health, Inc. (SYNH) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)---- $SYNH #classaction--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of those who acquired Syneos Health, Inc. (“Syneos” or the “Company”) (NASDAQ: SYNH) securities during the period from September 9, 2020 through November 3, 2022 (the “Class Period”). Investors have until September 25, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Syneos opera.

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Syneos Health, Inc. (SYNH) Investors

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Syneos business and prospects, resulting in its stock trading at inflated prices.

SYNH INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Syneos Health, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead the Syneos Class Action Lawsuit

Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Syneos Health (SYNH) Q2 Earnings Expected to Decline

FSD Pharma

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, today announces that the Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201. In January 2022, Syneos Health (NASDAQ.

Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201

Human Resources Leader with Nearly 30 Years of Experience and Commitment to Professional Services Environment Human Resources Leader with Nearly 30 Years of Experience and Commitment to Professional Services Environment

Syneos Health Appoints Hillary Bochniak as Chief Human Resources Officer

Syneos Health (SYNH) partners with uMotif to deliver the patient-centric eClinical platform.

Syneos Health (SYNH) Collaborates With uMotif for New Platform

Integrated eCOA & ePRO Solution Taps Company's Decentralized Capabilities and Technology Expertise Integrated eCOA & ePRO Solution Taps Company's Decentralized Capabilities and Technology Expertise

Syneos Health and uMotif Partner to Deliver Patient-centric eClinical Platform

NEW YORK , June 23, 2023 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Syneos Health Inc. ("SYNH" or the "Company") (NASDAQ: SYNH) stock prior to May 9, 2023 . You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of SYNH.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Syneos Health Inc. by a consortium of private investment firm affiliates composed of Elliott Investment Management, Patient Square Capi

Syneos Health's (SYNH) purchase price represents a 24% premium to its unaffected closing stock price prior to the announcement. Margin pressure continues to weigh on the stock.

Syneos Health (SYNH) Sell-Off Appears Strategic Amid Margin Woes

Newly Created Role Demonstrates Commitment to Improve Diversity in Clinical Trials and Commercialization Across Organization Newly Created Role Demonstrates Commitment to Improve Diversity in Clinical Trials and Commercialization Across Organization

Syneos Health Appoints Batisha Anson to Global Head, Patient Diversity and Health Equity

Healthcare Businesswomen's Association Spotlights Jennifer Sozio and Caitlin Purinai for Biopharma Industry Impact Healthcare Businesswomen's Association Spotlights Jennifer Sozio and Caitlin Purinai for Biopharma Industry Impact

Syneos Health Leaders Recognized by HBA

Company Executives Honored for Notable Biopharmaceutical Industry Impact Company Executives Honored for Notable Biopharmaceutical Industry Impact

Syneos Health Leaders Recognized as PM360 2023 ELITE Award Recipients

Syneos Health (SYNH) is set to become private company following a $7.1 billion merger deal to be acquired by a private investment consortium.

News for Syneos Health Stock (SYNH)